pazopanib — Medica
Thyroid carcinoma, differentiated
Initial criteria
- age ≥ 18 years
- Patient has papillary or follicular thyroid carcinoma refractory to radioactive iodine therapy OR patient has oncocytic (formerly Hürthle cell) carcinoma
Approval duration
1 year